Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MANTA-RAy: Filgotinib semen parameters in rheumatic diseases
NCT03926195Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- May 2019
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and 1 more comparing Filgotinib with Placebo (2 arms). Primary endpoint: Percentage of Participants With a >= 50% Decrease From Baseline in Sperm Concentration at Week 13. Started May 2019; status: completed.
02
Drugs
filgotinib
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on NCT03926195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926195.